toxylact: a07ba chargoal preparations
The first professional lActological database in the word
Charcoal preparations (ATC A07BA) are intestinal adsorbents based on activated charcoal, used mainly for acute poisoning and, at lower doses, for symptomatic management of diarrhea, with negligible systemic absorption and a very low theoretical risk during breastfeeding.atcddd.fhi+3
ATC A07BA classification
ATC subgroup A07BA comprises “Charcoal preparations” within the wider class A07B intestinal adsorbents. These medicines are classified under the alimentary tract group A and are distinguished from bismuth and other mineral adsorbents by their carbon-based, highly porous structure.atcddd.fhi+3
Pharmacology and mechanism
Activated charcoal has an exceptionally large internal surface area that allows non‑specific adsorption of many drugs, phytotoxins, and chemicals within the gastrointestinal lumen. By binding these substances, charcoal reduces their absorption from the gut and promotes their elimination in the feces, thereby limiting systemic toxicity.ncbi.nlm.nih+4
Therapeutic indications
Clinically, A07BA charcoal preparations are primarily used for gastrointestinal decontamination after ingestion of potentially toxic doses of drugs or other poisons, ideally within one hour of exposure. At lower doses, some oral charcoal products are also used as intestinal adsorbents for common diarrhea, with defined daily doses in the ATC/DDD system based on this indication.medicalguidelines.msf+6
Dosage and administration (context for risk)
For acute poisoning, typical single doses are around 1 g/kg (for example 50 g in adults) given as a suspension; repeated smaller doses may be used over 24 hours in selected cases. For common diarrhea, considerably lower doses are used, resulting in much lower total charcoal exposure and reinforcing the expectation of minimal systemic and milk transfer.medicalguidelines.msf+3
Pharmacokinetics relevant to lactation
Activated charcoal is not absorbed from the intact gastrointestinal tract; it remains confined to the lumen and is excreted unchanged in the feces. Because systemic bioavailability is essentially zero, passage of intact charcoal particles into human milk is not expected and would be, at most, negligible from a toxicological perspective.ncbi.nlm.nih+3
Maternal safety considerations
Common adverse effects in adults include nausea, vomiting, constipation, and, rarely, aspiration if administered to patients with impaired airway reflexes. Contraindications include unprotected airway, risk of gastrointestinal perforation or obstruction, and situations where activated charcoal does not effectively adsorb the ingested substance (for example, caustics, iron, lithium, alcohols), which affects clinical utility but not specifically lactation safety.ncbi.nlm.nih+3
Lactation safety profile
Given the lack of gastrointestinal absorption, charcoal preparations used orally in usual therapeutic doses are considered compatible with breastfeeding, with no expected clinically relevant exposure for the breastfed infant via milk. The main lactation‑related concern is the underlying maternal condition (for example, serious poisoning requiring intensive care) rather than the charcoal itself, and breastfeeding decisions should be guided by maternal stability and the nature of the toxin.ncbi.nlm.nih+3
Potential effects on the breastfed infant
Direct toxic effects in the infant from maternal oral charcoal are not anticipated because transfer into milk should be negligible and charcoal itself is inert when not ingested. If the mother’s poisoning involves agents that can pass into breast milk, separate risk assessment of the specific toxin is necessary, and temporary interruption of breastfeeding may be required for those substances, independently of charcoal administration.ncbi.nlm.nih+3
Practical use in breastfeeding women
For breastfeeding women receiving charcoal after accidental poisoning, a case‑by‑case assessment should weigh the risk of the ingested substance, the timing of exposure, and alternative feeding options; charcoal per se rarely necessitates interruption of breastfeeding. When low‑dose charcoal is used as an intestinal adsorbent for mild, self‑limited diarrhea, it is generally acceptable to continue breastfeeding without special dose‑timing measures, while maintaining adequate maternal hydration and monitoring the infant for signs of infectious diarrhea.atcddd.fhi+3
Risk–benefit considerations
In the context of emergency toxicology, the substantial benefit of activated charcoal in reducing systemic absorption of many poisons clearly outweighs its minimal theoretical risk during lactation. For over‑the‑counter use in diarrhea, the favorable safety profile, lack of absorption, and absence of expected milk transfer support its classification as a low‑risk option in breastfeeding, provided that prolonged or unnecessary use is avoided and that the cause of diarrhea is correctly evaluated.atcddd.fhi+7



